May 18, 2020 / 12:30PM GMT
Operator
Good morning, and welcome to the Moderna's Conference Call. (Operator Instructions) Please be advised that the call is being recorded. At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna.
Lavina Talukdar - Moderna, Inc. - Head of IR
Thank you, operator. Good morning, everyone, and welcome to Moderna's Conference Call to discuss the interim Phase I data for mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website.
Speaking on today's call are Stéphane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; Stephen Hoge, our President; and Lorence Kim, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ
Moderna Inc To Discuss SARS-CoV-2 Vaccine (mRNA-1273) Interim Phase 1 Data Transcript
May 18, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers